Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Modelling Myelofibrosis in Vivo: Success With NSG-S, With Drs. Beth Psaila and Hamza Celik

Modelling Myelofibrosis in Vivo: Success With NSG-S, With Drs. Beth Psaila and Hamza Celik

FromThe Hematologist


Modelling Myelofibrosis in Vivo: Success With NSG-S, With Drs. Beth Psaila and Hamza Celik

FromThe Hematologist

ratings:
Length:
15 minutes
Released:
Mar 4, 2022
Format:
Podcast episode

Description

In this podcast, Contributing Editor Dr. Beth Psaila has a conversation with Dr. Hamza Celik. They discuss a Cancer Discovery article covered by Dr. Psaila in her most recent Diffusion article titled, “Modeling Myelofibrosis in Vivo: Success With NSG-S.” In the article, Dr. Psaila discusses an optimized approach for engrafting myelofibrosis CD34+ stem/progenitor cells from peripheral blood of patients into immunodeficient mice called NSG-S, as a successful model of myelofibrosis in an in vivo setting. You can access her Diffusion article online at https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V19.2.202222/484169/Modelling-Myelofibrosis-in-Vivo-Success-With-NSG-S. Additional information about Dr. Celik: Dr. Hamza Celik joined Incyte Research Corporation in 2020 as a principal investigator in pre-clinical pharmacology. At the time he contributed to the article referenced in Dr. Psaila’s Diffusion and in this podcast, he was in the process of completing his postdoctoral work in normal and malignant hematopoiesis under the supervision of Dr. Grant Challen at the Washington University of St. Louis.  Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
Released:
Mar 4, 2022
Format:
Podcast episode

Titles in the series (100)

The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.